2
|
Sharif-Askari E, Alam A, Rhéaume E, Beresford PJ, Scotto C, Sharma K, Lee D, DeWolf WE, Nuttall ME, Lieberman J, Sékaly RP. Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. EMBO J 2001; 20:3101-13. [PMID: 11406587 PMCID: PMC150191 DOI: 10.1093/emboj/20.12.3101] [Citation(s) in RCA: 97] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The protease granzyme B (GrB) plays a key role in the cytocidal activity during cytotoxic T lymphocyte (CTL)-mediated programmed cell death. Multiple caspases have been identified as direct substrates for GrB, suggesting that the activation of caspases constitutes an important event during CTL-induced cell death. However, recent studies have provided evidence for caspase-independent pathway(s) during CTL-mediated apoptosis. In this study, we demonstrate caspase-independent and direct cleavage of the 45 kDa unit of DNA fragmentation factor (DFF45) by GrB both in vitro and in vivo. Using a novel and selective caspase-3 inhibitor, we show the ability of GrB to process DFF45 directly and mediate DNA fragmentation in the absence of caspase-3 activity. Furthermore, studies with DFF45 mutants reveal that both caspase-3 and GrB share a common cleavage site, which is necessary and sufficient to induce DNA fragmentation in target cells during apoptosis. Together, our data suggest that CTLs possess alternative mechanism(s) for inducing DNA fragmentation without the requirement for caspases.
Collapse
Affiliation(s)
- Ehsan Sharif-Askari
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Antoine Alam
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Eric Rhéaume
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Paul J. Beresford
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Christian Scotto
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Kamal Sharma
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Dennis Lee
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Walter E. DeWolf
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Mark E. Nuttall
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Judy Lieberman
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| | - Rafick-Pierre Sékaly
- Laboratoire d’Immunologie, Département de Microbiologie et d’Immunologie, Université de Montréal, Montréal, H3C 3J7, Department of Microbiology and Immunology and Department of Experimental Medicine, McGill University, Montréal, H3A 2B4, Canada, Center for Blood Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, Department of Medicinal Chemistry, Department of Mechanistic Enzymology and Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA Present address: Sanofi-Synthelabo, Département Cardiovasculaire, Toulouse Cedex, F-31036, France Present address: Procrea Biosciences Inc., Genomic Program, Montreal, Quebec, H4P 2R2, Canada Present address: Sunesis Pharmaceuticals Inc., Department of Chemistry, Redwood City, CA 94063, USA Corresponding author e-mail:
| |
Collapse
|